Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ. Ursini-Siegel J, et al. Among authors: lavoie c. Mol Cell Biol. 2007 Sep;27(18):6361-71. doi: 10.1128/MCB.00686-07. Epub 2007 Jul 16. Mol Cell Biol. 2007. PMID: 17636013 Free PMC article.
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.
Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, Park M, Chodosh L, Strathdee D, Norman JC, Muller WJ. Boulay PL, et al. Among authors: lavoie c. Cancer Res. 2016 May 1;76(9):2662-74. doi: 10.1158/0008-5472.CAN-15-2782. Epub 2016 Mar 1. Cancer Res. 2016. PMID: 26933086 Free PMC article.
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ. Smith HW, et al. Among authors: lavoie c. Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4. Nat Commun. 2019. PMID: 31263101 Free PMC article.
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy.
Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, Park M, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, Muller WJ. Hirukawa A, et al. Among authors: lavoie c. Cell Rep. 2019 Oct 8;29(2):249-257.e8. doi: 10.1016/j.celrep.2019.08.105. Cell Rep. 2019. PMID: 31597089 Free article.
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC. Dumont N, et al. Among authors: lavoie c. Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14. Nanomedicine. 2019. PMID: 30654182
Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.
Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. Hulea L, et al. Among authors: lavoie c. Cell Metab. 2018 Dec 4;28(6):817-832.e8. doi: 10.1016/j.cmet.2018.09.001. Epub 2018 Sep 20. Cell Metab. 2018. PMID: 30244971 Free PMC article.
180 results